Search results
- (-) Remove Press releases filter Press releases
John Dawson awarded CBE in the Queen's New Year Honours List
Oxford, UK – 31 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for LentiVector® Platform
Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy g
John Dawson to retire from Oxford Biomedica
Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene a
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease
- Negligible financial impact on Oxford Biomedica in the short and medium term
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new custome
Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director
Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy
2021 Annual report and accounts & AGM notification
London, UK – 27 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and
Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titers above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector
Bedford, Massachusetts - May 6, 2022: Oxford Biomedica Solutions, LLC.